I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals reported a narrowed net loss of USD 20 million for H1 FY26, down from USD 24.1 million, despite a 5.8% revenue decline to USD 9.8 million due to product transition. R&D and selling expenses decreased significantly, while G&A costs rose slightly. The company also noted clinical progress in CID-103 and ITP trials.
- CASI Pharmaceuticals posted first-half 2026 revenue of USD 9.8 million, down 5.8% on a transition from EVOMELA to locally made MAFALAN. * Net loss narrowed to USD 20 million, improving from USD 24.1 million; cash and cash equivalents fell to USD 3.8 million at June 30. * R&D expenses dropped 37.8% to USD 2.3 million, while selling and marketing costs slid 18.5% to USD 7.5 million. * General and administrative expenses rose 3.6% to USD 14.3 million on higher legal fees, partly offset by lower labor costs. * Clinical progress included first patient dosed in a China Phase 1⁄2 CID-103 AMR trial; ITP Part A enrollment completed at 1,200 mg. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608140645ACCESSWRNAPR_____1205409) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)